Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ipsen (GB:0MH6)
LSE:0MH6
Holding GB:0MH6?
Track your performance easily
0MH6 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€99.50 - €126.30
Previous Close€109.95
Volume1.79K
Average Volume (3M)30.73K
Market Cap
€9.12B
Enterprise Value€8.65B
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€695.30M
Price to Earnings (P/E)13.3
Beta0.62
Next Earnings
Feb 13, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 30, 2024Dividend Yield1.09%
Share Statistics
EPS (TTM)8.24
Shares OutstandingN/A
10 Day Avg. Volume33,601
30 Day Avg. Volume30,733
Standard Deviation0.10
R-Squared0.16
Alpha0.00547
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2.81
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€134.00Price Target Upside21.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Ipsen News
PremiumCompany Announcements
Ipsen Wins Second Shingo Prize for Excellence
PremiumCompany Announcements
Ipsen’s Kayfanda® Gets EU Approval for Rare Liver Disease
PremiumCompany Announcements
Ipsen’s New PBC Treatment Iqirvo Gains EU Approval
PremiumCompany Announcements
Ipsen Nears EU Approval for Liver Disease DrugsPremiumCompany Announcements
Ipsen Secures Deal for Promising Cancer Drug FS001
PremiumCompany Announcements
Ipsen Eyes Expanded Market for Cabometyx After Trial Success
PremiumCompany Announcements
Ipsen’s Iqirvo® Wins FDA Nod for Liver Disease
PremiumCompany Announcements
Ipsen Bolsters Oncology Research with MarengoOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.93% Mutual Funds
<0.01% Other Institutional Investors
92.40% Public Companies and
Individual Investors
0MH6 FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest share price was €99.50 and its highest was €126.30 in the past 12 months.
What is Ipsen’s market cap?
Currently, no data Available
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Feb 13, 2025 which is in 95 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Jul 25, 2024. The company reported €4.78 earnings per share for the quarter, beating the consensus estimate of €4.66 by €0.12.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Undervalued.
Does Ipsen pay dividends?
Ipsen pays a Annually dividend of €1.2 which represents an annual dividend yield of 1.09%. See more information on Ipsen dividends here
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €4.78 in its last earnings report, beating expectations of €4.66. Following the earnings report the stock price went down -6.795%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in GB:0MH6
---
Ipsen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.53%
12-Months-Change
Fundamentals
Return on Equity
17.82%
Trailing 12-Months
Asset Growth
7.50%
Trailing 12-Months
Company Description
Ipsen
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: specialty care and primary care. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
---
0MH6 Stock 12 Month Forecast
Average Price Target
€134.00
▲(21.88% Upside)
Technical Analysis
Best Analysts Covering 0MH6
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+13.37%
reiterated a buy rating 10 months ago
Copying Delphine Le Louet's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +13.37% per trade.
---